| Download | - View final version: The synergistic effects of sulfated lactosyl archaeol archaeosomes when combined with different adjuvants in a murine model (PDF, 832 KiB)
- View supplementary information: The synergistic effects of sulfated lactosyl archaeol archaeosomes when combined with different adjuvants in a murine model (PDF, 334 KiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.3390/pharmaceutics13020205 |
|---|
| Author | Search for: Jia, Yimei1; Search for: Akache, Bassel1; Search for: Agbayani, Gerard1; Search for: Chandan, Vandana1; Search for: Dudani, Renu1; Search for: Harrison, Blair A.1; Search for: Deschatelets, Lise1; Search for: Hemraz, Usha D.2; Search for: Lam, Edmond2; Search for: Régnier, Sophie2; Search for: Stark, Felicity C.1ORCID identifier: https://orcid.org/0000-0002-7547-8493; Search for: Krishnan, Lakshmi1; Search for: Mccluskie, Michael J.1ORCID identifier: https://orcid.org/0000-0001-5538-1363 |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
- National Research Council of Canada. Aquatic and Crop Resource Development
|
|---|
| Format | Text, Article |
|---|
| Subject | archaeosome; vaccine adjuvant; glycolipid; sulfated lactosyl archaeo |
|---|
| Abstract | Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations. |
|---|
| Publication date | 2021-02-02 |
|---|
| Publisher | MDPI |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 0525e178-4aff-4e76-8c04-8c37314c7e3c |
|---|
| Record created | 2021-06-01 |
|---|
| Record modified | 2021-06-10 |
|---|
